Publications by authors named "Marlyane Motta"
Article Synopsis
- Ribociclib (LEE011), a CDK 4/6 inhibitor, showed promise in treating neuroblastoma and malignant rhabdoid tumors in pediatric patients during a phase I study, focusing on dosage, safety, and initial effectiveness.
- The study involved 32 patients aged 1-21, with escalated doses revealing some serious side effects, mainly related to blood cell counts, but manageable overall.
- The maximum tolerated dose was identified as 470 mg/m, while the recommended phase II dose was set at 350 mg/m, with stable disease observed in nine patients, suggesting potential for future combination therapies.
